The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients

BAKIRDÖĞEN S., EREN N., GÖKÇAY BEK S., Yavuz S.

ISTANBUL MEDICAL JOURNAL, vol.20, no.6, pp.524-527, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.4274/imj.galenos.2019.47048
  • Journal Name: ISTANBUL MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.524-527
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Introduction: Erythropoietin (Epo) is a hormone that is synthesized in the kidneys and that stimulates the erythropoiesis in the bone marrow. Epo has effects apart from the erythropoiesis. In chronic renal failure (CRF) patients, hemorrhagic diathesis is observed, and Epo production is decreased. Erythropoiesis-stimulating agents (ESAs) are widely used in the treatment of renal anemia in these patients. Our study aimed to investigate the effect of ESA5 use on platelet aggregation in peritoneal dialysis (PD) patients due to CRF.